U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06923761) titled 'EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)' on March 27.
Brief Summary: This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.
Study Start Date: May 21, 2023
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Malignancy
Intervention:
DRUG: Module 1 (GRWD5769 on its own as monotherapy)
Module 1 will initially be conducted in 4 study parts:
Part A: Monotherapy dose escalation (where the safety of increasing doses of GRWD5769 will initially be assessed in a small group of patients, overseen by a safety review comm...